The Chinese game of Go is one of the simplest, yet most complex games in the world. The objective of the game is to surround empty spaces or your opponent’s pieces (called stones) with your own, and remove surrounded pieces from the board. The complexity arises from the 19 by 19 grid containing 361 squares. The number of possible moves in a game exceeds the number of atoms in the universe.
Google’s AlphaGo clandestinely defeats some of the top Go players in the world. Image source: Pixabay.
In an online community known for attracting world class Go players, a previously unknown and enigmatic opponent going by the moniker “Master” emerged. Master played and won more than 50 consecutive games against some of the top players in the world. Among those players was Ke Jie, described as a 19-year-old prodigy, currently the top ranked Go player in the world. The unusual style of play led some to speculate that the Master might not be human. Those suspicions were confirmed in a tweetby Demis Hassabis, the CEO of DeepMind, a division of Alphabet’s (NASDAQ:GOOG) (NASDAQ:GOOGL) Google. The mysterious Master was AlphaGo, DeepMind’s artificial intelligence-based (AI) system.
holiday exchange: Iridium Communications Inc(IRDM)
- [By Jim Robertson]
Trump’s proposal to spin off air traffic control from the Federal Aviation Administration (FAA) bodes well for small cap satellite stock Iridium Communications (NASDAQ: IRDM), but theres a bigger opportunity for the Company in theInternet of Things (IoT) space. Technology company Harris Corporation (NYSE: HRS) is already a leading candidate to supply the FAA with real-time aircraft tracking data in partnership with Iridium Communications with the latter having a joint venture that has partnered with air traffic control authorities in Canada, Italy, Ireland and Denmark to provide air traffic surveillance (in cooperation with Harris).
- [By Peter Graham]
Small cap satellite stock Iridium Communications (NASDAQ: IRDM) reportedQ2 2017 earnings before the market opened on Thursday with results beating expectations. Total revenueincreased 2% to $111.6 million which consisted of $86.6 million of service revenue and $25.0 million of revenue related to equipment sales and engineering and support projects.Service revenue, which represents primarily recurring revenue from Iridium’s growing subscriber base, grew 4% and was 78% of total revenue. The Company ended the quarter with 913,000 total billable subscribers, which compares to 823,000 for the year-ago period and is up from 869,000 for the quarter ended March 31, 2017.Total billable subscribers grew 11% year-over-year, driven by growth in M2M and government customers. Net income was $24.8 million versus $26.9 million for the second quarter of 2016. The CEO commented:
holiday exchange: North American Energy Partners, Inc.(NOA)
- [By Lisa Levin]
In trading on Tuesday, energy shares slipped by 1.36 percent. Meanwhile, top losers in the sector included Northern Oil & Gas, Inc. (NYSE: NOG), down 9 percent, and North American Energy Partners Inc.(USA) (NYSE: NOA), down 6 percent.
holiday exchange: Opko Health Inc(OPK)
- [By Paul Ausick]
Opko Health Inc. (NASDAQ: OPK) dropped nearly 15% on Thursday to record a new 52-week low of $7.13 against a high of $12.15. The stock closed at $8.37 on Wednesday. Volume was more than 3 times the daily average of around 4.9 million shares. The company reported a worse-than-expected loss after markets closed last night.
- [By Cory Renauer]
Shares of multinational pharmaceutical and diagnostics companyOpko Health, Inc. (NASDAQ:OPK)are feeling the heat after reporting fourth-quarter and full-year 2016 earnings. Despite a major thumping late last year, the stock gave up another 10.5% as of 3:31 p.m. on Thursday.
- [By WWW.THESTREET.COM]
In the Lightning Round, Cramer was bullish on Kohlberg Kravis Roberts (KKR) , Opko Health (OPK) and Allergan (AGN) .
Cramer was bearish on Kimberly-Clark (KMB) , Novartis AG (NVS) , Chemours (CC) and Gulfport Energy (GPOR) .
- [By Demitrios Kalogeropoulos]
As for individual stocks, Cabela’s (NYSE:CAB) and Opko Health (NASDAQ:OPK) stood out by posting greater price declines than the broader market.
Opko Health fails a trial
Opko Health shares slumped 19% after the biotech announced disappointing results for one of its most advanced clinical trials. The human growth hormone injection, coded as hGH-CTP, failed to produce a statistically significant improvement over a placebo pill in its phase 3 study.
- [By Keith Speights]
Some biotech stocks have made shareholders a lot of money over the last decade. Few, though, have performed as well as Opko Health (NASDAQ:OPK), Incyte (NASDAQ:INCY), and China Biologic Products (NASDAQ:CBPO). These three biotech stocks turned an initial investment of $10,000 into more than $100,000 in just 10 years. Here’s how they did it.
- [By Paul Ausick]
Opko Health Inc. (NASDAQ: OPK) dropped about 3.6% Monday to post a new 52-week low of $6.37 after closing at $6.61 on Friday. The stock’s 52-week high is $12.15. Volume was about 25% higher than the daily average of around 4.6 million shares. The company had no specific news.
holiday exchange: Atkore International Group Inc. (ATKR)
- [By Spencer Israel]
3. Atkor International Group Inc (NYSE: ATKR) – Five of the six analyst ratings on the manufacturing holding company have been bullish. With the stock showing very strong technical support at $16, and currently trading at $16.68, Stockal's confidence meter is at 90%.
- [By Ben Levisohn]
Flexing the barbell strategy to balance Safe Havens with more cyclical exposures. In our view, industrials investors should be positioning their portfolio with a barbell strategy, with half of the exposure in Safe Havens like General Electric, Xylem (XYL), Danaher, Honeywell International, Roper Technologies (ROP), and AMETEK (AME), and the other half selectively in the cyclical names that are better positioned today, such as Pentair, HD Supply Holdings (HDS),Actuant (ATU), Atkore International Group (ATKR), Ingersoll-Rand, and Eaton (ETN). We still believe risk-reward is mostly balanced and that the macro will remain choppy into 2017, supporting a positioning in the defensive names. But if investor sentiment improves on not-worse news and earnings results, the more cyclical names could fare better.